American Heart Association/American College of Cardiology foundation guide to warfarin therapy

Journal of the American College of Cardiology

Volumn 41, Issue 9, 2003, Pages 1633-1652

  Hirsh, Jack ^a   Fuster, Valentin ^a   Ansell, Jack ^a   Halperin, Jonathan L ^a  

^a NONE

Author keywords

AHA ACC Scientific Statements; Anticoagulants; Coagulation; Hemorrhage; Thrombus

Indexed keywords

PROTHROMBIN; WARFARIN;

ACUTE HEART INFARCTION; ALGORITHM; ANTICOAGULATION; BLEEDING; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SELF EVALUATION; SKIN NECROSIS; STROKE; THROMBOSIS; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0037732826     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00416-9     Document Type: Review

References (255)

1. Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17:1371-7.
2. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 1982;257:11210-2.
3. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988;25:1-7.
4. Trivedi LS, Rhee M, Galivan JH, et al. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation. Arch Biochem Biophys 1988;264:67-73.
5. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974;71:2730-3.
6. Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974;249:6347-50.
7. Friedman PA, Rosenberg RD, Hauschka PV, et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients. Biochim Biophys Acta 1977;494:271-6.
8. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and gamma carboxy glutamic acid deficient prothrombins. J Biol Chem 1985;260:279-87.
9. Nelsestuen GL. Role of γ-carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 1976;251:5648-56.
10. Prendergast FG, Mann KG. Differentiation of metal ion-induced transitions of prothrombin fragment 1. J Biol Chem 1977;252:840-50.
11. Borowski M, Furie BC, Bauminger S, et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipids: conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. J Biol Chem 1986;261:14969-75.
12. Hauschka PV, Lian JB, Cole DEC, et al. Osteocatcin and matrix Gla protein: vitamin K dependent proteins in bone. Phys Rev 1989;990-1047.
13. Price PA. Role of vitamin K-dependent proteins in bone metabolism. Annu Rev Nutr 1988;8:565-83.
14. Maillard C, Berruyer M, Serre CM, et al. Protein S, a vitamin K-dependent protein is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 1992;130:1599-604.
15. Pan LC, Williamson MK, Price PA. Sequence of the precursor to rat bone γ-carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells. J Biol Chem 1985;260:13398-401.
16. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 1975;86:459-62.
17. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122-40.
18. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978;15:19-26.
19. O'Reilly RA. Vitamin K and other oral anticoagulant drugs. Annu Rev Med 1976;27:245-61.
20. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979;4:1-15.
21. O'Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, editors. The New Dimensions of Warfarin Prophylaxis: Advances in Experimental Medicine and Biology. New York, NY: Plenum; 1986:205-12.
22. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Brit J Clin Pharmacol 1998;45:525-38.
23. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin close requirement and risk of bleeding complications. Lancet 1999;353:717-9.
24. Higashi M, Veenstra DL, Wittkowsky AK, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
25. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-30.
26. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.
27. O'Reilly RA, Trager WF. Stereoselective interaction of phenylbutazone with 13C/12C labelled racemates of warfarin in man (abstr). Fed Proc 1978;37:545.
28. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;39:15-24.
29. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295:354-7.
30. O'Reilly RA. Stereoselective interaction of trimethoprimsulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5.
31. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974;53:1607-17.
32. O'Reilly RA, Trager WF, Rettie AE, et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987;42:290-4.
33. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981;141:458-9.
34. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-28.
35. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann NY Acad Sci 1968;151:913-31.
36. O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. N Engl J Med 1983;308:1229-30.
37. Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance: investigation of a rare phenomenon. Arch Intern Med 1985;145:499-501.
38. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997;98:240-4.
39. Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996;98:1619-25.
40. Mannucci PM. Genetic control of anticoagulation. Lancet 1999;353:688-9.
41. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
42. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992;117:878-9.
43. Bowles SK. Stereoselective disposition of warfarin in young and elderly subjects (abstr). Clin Pharmacol Ther 1994;55:172.
44. O'Reilly R, Rytand D. "Resistance" to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980;303:160-1.
45. Suttie JW, Mummah-Schendel LL, Shah DV, et al. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988;47:475-80.
46. Sadowski JA, Booth SL, Mann KG, et al. Structure and mechanism of activation of vitamin K antagonists. In: Poller L, Hirsh J. editors. Oral Anticoagulants. London, UK: Arnold; 1996:9-29.
47. Bovill EG, Lawson J, Sadowski J. et al. Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: implications for warfarin therapy. In: Ezekowitz MD, editors. The Heart as a Source of Systemic Embolisation. New York, NY: Marcel Dekker; 1992.
48. 1 content. Thromb Haemost 1997;77:504-9.
49. Richards RK. Influence of fever upon the action of 3,3-methylene bis-(4-hydroxoycoumarin). Science 1943;97:313-6.
50. Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med 1962;266:76-9.
51. Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methylthiotetrazole cephalosporins. Thromb Haemost 1984;51:358-61.
52. Weitekamp MR, Aber RC. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA 1983;249:69-71.
53. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh 1972;27:309-18.
54. Rothschild BM. Hematologic perturbations associated with salicylate. Clin Pharmacol Ther 1979;26:145-52.
55. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
56. Bell WR. Acetaminophen and warfarin: undesirable synergy. JAMA 1998;279:702-3.
57. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980;99:746-52.
58. Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol 1989;28:46-9.
59. Cazenave J-P, Packham MA, Guccione MA, et al. Effects of penicillin G on platelet aggregation, release and adherence to collagen. Proc Soc Exp Med 1973;142:159-66.
60. Brown CH II, Natelson EA, Bradshaw W, et al. The hemostatic defect produced by carbenicillin. N Engl J Med 1974;291:265-70.
61. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-32.
62. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51:1537-41.
63. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-9.
64. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention is ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
65. Weibert RT, Lorentz SM, Townsend RJ, et al. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8: 210-24.
66. Lorentz SM, Weibert RT. Potentiation of warfarin anticoagulation by topical testosterone treatment. Clin Pharm 1985;4:332-4.
67. Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA 1965;194:127-9.
68. Wells PS, Holbrook AM, Crowther NR, et al. The interaction of warfarin with drugs and food: a critical review of the literature. Ann Intern Med 1994;121:676-83.
69. Koch-Weser J, Sellers EM. Drug interactions with oral anticoagulants. N Engl J Med 1971;285:487-98.
70. Sellers E, Weser JK. Drug interactions with coumarin anticoagulants. N Engl J Med 1971;285:547-58.
71. Wittkowsky AK. Drug interactions updates: drugs, herbs and oral anticoagulation. J Thromb Thrombolysis 2001;12:67-71.
72. Wessler S, Gitel SN. Warfarin: from bedside to bench. N Engl J Med 1984;311:645-52.
73. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors. J Clin Invest 1993;92:2131-40.
74. Patel P, Weitz J, Brooker LA, et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma. Pediatr Res 1996;39:826-30.
75. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
76. Furie B, Diuguid CF, Jacobs M, et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy. Blood 1990;75:344-9.
77. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
78. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935;109:73-4.
79. Zucker S, Cathey MH, Sox PJ. et al. Standardization of laboratory tests for controlling anticoagulant therapy. Am J Clin Pathol 1970;53:348-54.
80. Poller L. Progress in standardisation in anticoagulant control. Hematol Rev 1987;1:225-41.
81. Latallo ZS, Thomson JM, Poller L. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy. Br J Haematol 1981;47:307-18.
82. Poller L, Tabemer DA. Dosage and control of oral anticoagulants: an international survey. Br J Haematol 1982;51:479-85.
83. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983;49:238-44.
84. Bussey HI, Force RW, Bianco TM, et al. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992;152:278-82.
85. Tripodi A, Chantarangkul V, Braga M, et al. Results of a multicenter study assessing the status of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost 1994;72:261-7.
86. Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? Arch Intern Med 1987;147:769-71.
87. World Health Organization Expert Committee on Biological Standardization. 33rd Report Technical Report Series No. 687. Geneva: World Health Organization; 1983.
88. Johnston M, Harrison L, Moffat K, et al. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med 1996;128:214-7.
89. Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-30.
90. College of American Pathologists Coagulation Survey Set: CG2-C. Northfield, IL: College of American Pathologists; 1997.
91. Taberner DA, Poller L, Thomson JM, et al. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalized ratios (INR). J Clin Patrol 1989;42:92-6.
92. Poller L, Hirsh J. Laboratory monitoring of anticoagulants. In: Poller L. Hirsh J, editors. Oral Anticoagulants. London, UK: Arnold; 1996:49-64.
93. Brien WF, Crawford L, Wood DE. Discrepant results in INR testing. Thromb Haemost 1994;72:986-7.
94. van den Besselaar AM, Evatt BL, Brogan DR. et al. Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation, and plasma. Am J Clin Pathol 1984;82:688-99.
95. Poller L, Triplett DA, Hirsh J, et al. The value of plasma calibrants in correcting coagulometer effects on international normalized ratios: an international multicenter study. Am J Clin Pathol 1995;103:358-65.
96. Poller L, Thomson JM, Taberner DA, et al. The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol 1994;86:112-7.
97. Poller L, Triplett DA, Hirsh J, et al. A comparison of lyophilized artificially depleted plasma and lyophilized plasma from warfarin treated in correcting for coagulometer effects on international normalized ratios. Am J Clin Pathol 1995;103:366-71.
98. Poggio M, van den Besselaar AM, van der Velde EA, et al. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 1989;62:868-74.
99. D'Angelo A, Seveso MP, D'Angelo SV, et al. Comparison of two automated coagulometers and the manual tilt tube method for determination of prothrombin time. Am J Clin Patrol 1989;92:321-8.
100. Poller L, Thomson JM, Taberner DA. Effect of automation on the prothrombin time test in NEQAS surveys. J Clin Pathol 1989;42:97-100.
101. Ray MJ, Smith IR. The dependence of the International Sensitivity Index on the coagulometer used to perform the prothrombin time. Thromb Haemost 1990;63:424-9.
102. van Rijn JL, Schmidt NA, Rutten WP. Correction of instrument and reagent based differences in determination of the International Normalised Ratio (INR) for monitoring anticoagulant therapy. Clin Chem 1989;35:840-3.
103. Thomson JM, Taberner DA, Poller L. Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. J Clin Pathol 1990;43:679-84.
104. Fairweather RB, Ansell J, van den Besselaar AM. et al. Laboratory monitoring of oral anticoagulant therapy: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:768-81.
105. Ng VL, Levin J, Corash L, et al. Failure of the International Normalized Ratio to generate consistent results within a local medical community. Am J Clin Pathol 1993;99:689-94.
106. Poller L. Laboratory control of oral anticoagulants. Br Med J 1987;294:1184.
107. Kazama M, Suzuki S, Abe T, et al. Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents. Thromb Haemost 1990;64:535-41.
108. van den Besselaar AM, Lewis SM, Mannucci PM, et al. Status of present and candidate International Reference Preparations (IRP) of thromboplastin for the prothrombin time: a report of the Subcommittee for Control of Anticoagulation. Thromb Haemost 1993;69:85.
109. Duncan EM, Casey CR, Duncan BM, et al. Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalized ratio and the international sensitivity index of thromboplastin. Thromb Haemost 1994;72:84-8.
110. Adcock DM, Kressen DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate on routine coagulation testing. Am J Clin Pathol 1997;107:105-10.
111. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
112. Della Valle P, Crippa L, Safa O, et al. Potential failure of the International Normalized Ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne (Paris) 1996;147 Suppl: 10-4.
113. Rapaport SI. Le DT. Thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995;333:665.
114. Le DT, Weibert RT, Sevilla BK, et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-8.
115. Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII, and X and their relationship to the International Normalized Ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997;8: 48-53.
116. Kornberg A, Francis CW, Pellegrini VD Jr, et al. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993;88:454-60.
117. James AH, Britt RP, Raskino CL. et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704-6.
118. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
119. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
120. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valve prostheses: the Leiden artificial valve and anticoagulation study. N Engl J Med 1995;333:11-7.
121. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-65.
122. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
123. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
124. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
125. Lucas FV, Duncan A, Jay R, et al. A novel whole blood capillary technique for measuring prothrombin time. Am J Clin Pathol 1987;88:442-6.
126. Yano Y, Kambayashi J, Murata K, et al. Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. Thromb Res 1992;66:583-90.
127. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. J Thromb Thrombolysis 1996;3:377-83.
128. Jennings I, Luddington RJ, Baglin T. Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. J Clin Pathol 1991;44:950-3.
129. McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. Arch Intern Med 1992;152:589-92.
130. Tripodi A, Arbini AA, Chantarangkul V, et al. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio? Thromb Haemost 1993;70:921-4.
131. Oberhardt BJ, Dermott SC, Taylor M, et al. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. Clin Chem 1991;37:520-6.
132. Rose VL. Dermott SC, Murray BF, et al. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. Arch Patrol Lab Med 1993;117:611-7.
133. Fabbrini N, Messmore H, Balbale S, et al. Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting (abstr). Blood 1995;86 Suppl:869a.
134. Tripodi A, Chantarangkul V, Clerici M, et al. Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy-overview of the assessment of conformity to the calibration model. Thromb Haemost 1997;78:855-8.
135. Kaatz AA, White RH, Hill J, et al. Accuracy of laboratory and portable monitor international normalized ratio determinations: comparison with a criterion standard. Arch Intern Med 1995;155:1861-7.
136. Ansell J, Becker D, Andrew M, et al. Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing (abstr). Blood 1995;86 Suppl:864a.
137. Andrew M. Marzinotto V, Adams M, et al. Monitoring of oral anticoagulant therapy in pediatric patients using a new microsample PT device. Blood 1995;86 Suppl:863a.
138. Ansell JE, Zweig S, Meyer B, et al. Performance of the AvocetPT prothrombin time system (abstr). Blood 1998;92 Suppl:112b.
139. Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 1993;153:1441-7.
140. White RH, McCurdy SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. Ann Intern Med 1989;111:730-7.
141. Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial (abstr). J Gen Intern Med 1997;12:66.
142. Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor: a pilot investigation. Thromb Res 1997;85:77-82.
143. Erdman S, Vidne B, Levy MJ. A self-control method for long-term anticoagulation therapy. J Cardiovasc Surg 1974;15:454-7.
144. Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med 1989;149:2509-11.
145. Ansell J, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185-9.
146. Bernardo A. Experience with patient self-management of oral anticoagulation. J Thromb Thrombolysis 1996;2:321-5.
147. Horstkotte D, Piper C, Wiemer M, et al. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy (abstr). Eur Heart J 1996;17 Suppl:230.
148. Sawicki PT, Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999;281:145-50.
149. Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001;72:44-8.
150. Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000;83:661-5.
151. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet 2000;356:97-102.
152. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, et al. Comparison of the quality of oral anticoagulation therapy through patient self-management versus management by specialized anticoagulation clinics in the Netherlands (abstr). Thromb Haemost 2001;86 Suppl: OC161.
153. Kaatz S, Elston-Lafata J, Gooldy S. Anticoagulation therapy home and office evaluation (AT HOME) study (abstr). Thromb Haemost 2001;86 Suppl:P779.
154. Wilson R, James AH. Computer assisted management of warfarin treatment. Br Med J 1984;289:422-4.
155. White RH, Mungall D. Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care. Ther Drug Monit 1991;13:46-50.
156. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage: European Concerted Action on Anticoagulation. Lancet 1998;352:1505-9.
157. Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993;46:299-303.
158. Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. Thromb Res 1998;91:237-40.
159. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-2.
160. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-3.
161. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136-40.
162. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. Ann Intern Med 2002;137:251-4.
163. Park BK, Scott AK, Wilson AC, et al. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984;18:655-62.
164. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119 Suppl:22S-38S.
165. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
166. Landefeld CS, Rosenblatt MW. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989;87:153-9.
167. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-81.
168. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-5.
169. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-32.
170. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-31.
171. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108 Suppl:276s-90s.
172. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9.
173. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95.
174. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-11.
175. Sindet-Pedersen S, Ramstrom G, Bernvil S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989;320:840-3.
176. Souto JC, Oliver A, ZuaZu-Jausoro I, et al. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg 1996;54:27-32.
177. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994;71:196-201.
178. Hanania G. Management of anticoagulants during pregnancy. Heart 2001;86:125-6.
179. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000;101:1083-6.
180. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983;103:325-7.
181. Lao TT, de Swiet M, Letsky E, et al. Prophylaxis of thromboembolism in pregnancy: an alternative. Br J Obstet Gynecol 1985;92:202-6.
182. Verhagen H. Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl. Acta Med Scand 1954;148:455-67.
183. Weinberg AC, Lieskovsky G, McGehee WG, et al. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia. J Urol 1983;130:352-4.
184. Broekmans AW, Bertina RM, Loeliger EA, et al. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983;49:244-51.
185. Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986;104:659-60.
186. Samama M, Horellou MH, Soria J, et al. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment. Thromb Haemost 1984;51:332-3.
187. Grimaudo V, Gueissaz F, Hauert J, et al. Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ 1989;298:233-4.
188. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
189. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959;II:981-9.
190. Francis CW, Marder VJ, Evans CM, et al. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374-8.
191. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771-4.
192. Taberner DA, Poller L, Burslem RW, et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. BMJ 1978;1:272-4.
193. Poller L, McKernan A, Thomson JM, et al. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309-12.
194. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990;112:423-8.
195. Poller L, MacCallum PK, Thomson JM, et al. Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study. Br Heart J 1990;63:231-3.
196. Dale C, Gallus A, Wycherley A, et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ 1991;303:224.
197. Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. BMJ 1991;303:219-20.
198. Poller L, Thomson JM, MacCallum PK, et al. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. Clin Appl Thromb Hemost 1995;1:267-73.
199. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
200. Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 1995;332:1710-11.
201. Hirsh J, Lee A. How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102-10.
202. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
203. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-94.
204. Lagerstedt CI, Fagher BO, Albrechtsson U, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
205. Schulman S, Rhedin A. Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
206. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-8.
207. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
208. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant: a case-control study. Thromb Haemost 1996;76:187-9.
209. Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 1997;77:221-2.
210. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
211. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randemised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-96.
212. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
213. Veterans Administration Cooperative Study. Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA 1973;225:724-9.
214. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972;222:541-8.
215. Medical Research Council Group. Assessment of short-term anticoagulant administration after cardiac infarction: report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis. BMJ 1969;1:335-42.
216. Cairns JA, Hirsh J, Lewis HD Jr, et al. Antithrombotic agents in coronary artery disease. Chest 1992;102 Suppl:456s-81s.
217. Goldberg RJ, Gore JM, Dalen JE, et al. Long-term anticoagulant therapy after acute myocardial infarction. Am Heart J 1985;109:616-22.
218. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction: a new approach to old data. Eur J Clin Pharmacol 1983;24:333-6.
219. Sixty-Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-94.
220. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
221. van Es RF. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis-2. Abstract presented at the 22nd meeting of the European Society of Cardiology, Amsterdam, 2000. Available at: http://www.cardiosource.com/trials/trial?searchtoc=A&published= n&uid=MDTRIALS.42057.
222. Brower MA. Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2. Abstract presented at the 22nd meeting of the European Society of Cardiology, Amsterdam, 2000. Available at: http://www.cardiosource.com/trials/ trial?searchtoc=A&published=n&uid=MDTRIALS.32678.
223. Hurlen M, Smith P, Abdelnoor M, et al. Warfarin Aspirin Reinfarction Study II: Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. Abstract presented at the 23rd meeting of the European Society of Cardiology, Stockholm, 2001. Available at: http://www.escardio.org/congress/Stock01/ hotline/slides/WARIS%20II%20Press.pdf.
224. Fiore LD, Ezekowitz MD, Brophy Mt, et al. Department of Veterans Affairs Cooperative Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557-63.
225. Kretschmer G, Wenzl E, Schemper M, et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1988;1:797-8.
226. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
227. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 1992;327:141-5.
228. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
229. Cohen M, Théroux P, Weber S. et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-81.
230. Williams DO, Kirby MG, McPherson K, et al. Anticoagulant treatment in unstable angina. Br J Clin Pract 1986;40:114-6.
231. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end point analysis from the ATACS trial. Circulation 1994;89:81-8.
232. Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation 1998;98:1064-70.
233. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985;72:1059-63.
234. Gohlke-Barwolf, Acar J, Oakley C, et al. Guidelines for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 1995;16:1320-30.
235. Stein PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1998;114 Suppl:602S-10S.
236. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coil Cardiol 1998;32:1486-588.
237. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996;335:407-16.
238. The Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
239. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
240. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12.
241. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;1:175-9.
242. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
243. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
244. Albers GW, Sherman DG, Gress DR, et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991;30:511-8.
245. Atwood J, Albers G. Anticoagulation and atrial fibrillation. Herz 1993;18:27-38.
246. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
247. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
248. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-64.
249. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001;38:1231-66.
250. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995;108:444S-56S.
251. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the preventionpnrnotl of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
252. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-31.
253. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000;54:288-94.
254. Mas JL, Arquizan C, Lamy C, Zuber M, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-6.
255. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK 2). Arch Intern Med 1998;158:1513-21.